Feed MRNA
MR

Moderna

MRNA · NASDAQ

$190.01 +0.57% (+$1.07)
1M +30.55%
Market Cap $75.0B
P/E Ratio -
Div. Yield -
ROE 39.21%
Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/B 11.09x
P/S 33.65x
EV/FFO N/A
Growth
0 /100
Declining
Book val. growth 23.24%
Rev. growth 53.13%
FCF growth N/A
Profitability
0 /100
Weak
Op. margin 149.01%
Gross margin 12.57%
FCF margin 54.89%
Quality
3 /100
Poor
ROA 28.75%
ROIC 39.97%
Asset turnover 0.20x
Debt
69 /100
Low
Int. coverage -122.80x
Debt/Equity 0.19x
Current ratio 2.29x
Stability
50 /100
Moderate
EPS volatility 106.63%
Beta 0.90x
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about MRNA
Online

About the company

Moderna (MRNA) is a biopharmaceutical company specializing in the development of innovative drugs and vaccines. Their primary focus is on mRNA technology, which enables the creation of therapeutic and preventive products with high efficacy and safety. Moderna gained significant attention for its development of a COVID-19 vaccine, which has been approved and successfully deployed worldwide. Moderna stock is suitable for investors interested in the biotechnology sector and seeking opportunities in the field of therapeutic innovations and vaccines. Add Moderna stock to your watchlist on Bulios and be the first to receive updates on new developments, medical breakthroughs, and vaccines from this prominent company.

Sector

Healthcare

Industry

Biotechnology

CEO

Stéphane Bancel

Employees

4,700

Headquarters

Cambridge

Upcoming events

05 NOV

Earnings

Upcoming earnings report

32d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.